眼压对青光眼管理临床决策的影响
该回顾性多中心队列研究利用SOURCE眼科数据仓库,分析2009年10月至2022年1月间眼压在12-25 mmHg的青光眼患者就诊记录,评估眼压水平如何影响启动或升级降眼压治疗的决策。结果显示治疗率随眼压升高而增加,眼压≥22 mmHg时治疗率加速最明显;混合效应逻辑回归显示22 mmHg对治疗启动的影响大于更低眼压(OR 1.11,95%CI 1.08-1.14),提示历史22 mmHg切点仍影响临床决策。
要点
- 眼压越高,启动或升级降眼压治疗的比例越高。
- 眼压22 mmHg及以上时治疗率加速最明显。
- 22 mmHg对治疗启动的OR为1.11(95%CI 1.08-1.14),提示历史切点仍影响决策。
核心结论
- 临床医生总体将眼压作为连续风险因素使用,但历史22 mmHg切点仍影响青光眼治疗决策。
研究设计与样本
- 回顾性多中心队列研究,使用SOURCE眼科数据仓库,纳入2009年10月至2022年1月间眼压12-25 mmHg的青光眼患者就诊记录。
- 患者平均年龄69.5岁(SD 10.8),58.1%的就诊涉及女性患者。
主要发现
- 降眼压治疗率随眼压水平升高而增加,眼压≥22 mmHg时治疗率加速最明显。
- 混合效应逻辑回归显示,指示眼压22 mmHg对治疗启动的影响大于更低指示眼压(OR 1.11,95%CI 1.08-1.14)。
关键数值与推荐
- 主要结局为就诊后启动或升级降眼压治疗,定义为1周内新开降眼压药物、4周内激光治疗或8周内青光眼手术。
临床怎么用
- 临床决策中应意识到22 mmHg历史切点可能仍影响治疗启动,可借助临床决策支持更一致地将眼压作为连续风险因素使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Understanding of intraocular pressure (IOP) as a continuous risk factor for glaucoma has evolved over time, and IOP reduction is widely acknowledged as the mainstay of treatment. However, the impact of specific IOP levels on clinical decision-making remains an underexplored topic. OBJECTIVE: To assess how IOP levels influence the decision to initiate or escalate glaucoma therapy in clinical practice. DESIGN, SETTING, AND PARTICIPANTS: In this retrospective, multicenter cohort study, the Sight Outcomes Research Collaborative (SOURCE) ophthalmology data repository was used to identify clinic encounters between October 2009 and January 2022 for patients with glaucoma with IOPs ranging from 12 mm Hg to 25 mm Hg. Data analysis was performed from July 2024 to September 2025. MAIN OUTCOMES AND MEASURES: The primary outcome was whether IOP-lowering therapy was initiated or escalated after each clinic encounter, defined as a new prescription for IOP-lowering medication within 1 week of the encounter, laser treatment within 4 weeks, or glaucoma surgery within 8 weeks. The rate of treatment initiation at different IOP levels was measured, and then mixed-effects logistic regression was used to model the odds of treatment initiation at specific indicator IOP levels. RESULTS: This analysis included 1 866 801 clinic encounters from 184 504 eyes of 94 232 unique patients across 7 sites in SOURCE. Mean (SD) patient age was 69.5 (10.8) years, and of the total clinic encounters, 1 084 827 (58.1%) included female patients. The rate of IOP-lowering treatment increased with higher IOP levels, with the largest acceleration in treatment rate at IOPs of 22 mm Hg or higher. With mixed-effects logistic regression modeling, an indicator IOP of 22 mm Hg had a greater effect on treatment initiation (odds ratio, 1.11; 95% CI, 1.08-1.14) compared with lower indicator IOPs. CONCLUSIONS AND RELEVANCE: In this cohort study, while clinicians seem to generally use IOP as a continuous risk factor in their treatment patterns, with higher rates of glaucoma therapy at increasing IOP levels, these findings suggest that the historical IOP cutoff of 22 mm Hg may still influence clinician decision-making in glaucoma management. Improved clinical decision support may be useful to assist clinicians with using IOP as a continuous risk factor in their decision-making.
引用
- Polski A, Brintz BJ, Hess R, et al. Influence of Intraocular Pressure on Clinical Decision-Making in Glaucoma Management. JAMA Ophthalmol. 2026. PMID: 41505118. doi:10.1001/jamaophthalmol.2025.5593
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。